Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 4/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | ADH4 | P08319 | 1/20 | 0.33 |
| ▸ | ADH7 | P40394 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25516874 | 0.86 | FDPS (0.34) | OPRM1FDPSSPHK1LMNAMAPT | |
| SCHEMBL20781969 | 0.85 | OPRM1 (0.36) | OPRM1FDPSSPHK1LMNAMAPT | |
| SCHEMBL25748461 | 0.82 | LMNA (0.38) | FDPSSPHK1LMNAMAPTTSHR | |
| SCHEMBL24486062 | 0.82 | FDPS (0.36) | OPRM1FDPSSPHK1LMNADNM1 | |
| SCHEMBL25516925 | 0.82 | FDPS (0.36) | OPRM1FDPSSPHK1LMNADNM1 | |
| SCHEMBL25518417 | 0.82 | FDPS (0.36) | OPRM1FDPSSPHK1LMNADNM1 | |
| SCHEMBL22458297 | 0.81 | OPRM1 (0.38) | OPRM1FDPSSPHK1LMNAMAPT | |
| SCHEMBL22457670 | 0.81 | OPRM1 (0.38) | OPRM1FDPSSPHK1LMNAMAPT | |
| SCHEMBL21160999 | 0.77 | FDPS (0.37) | OPRM1FDPSLMNADNM1 | |
| SCHEMBL21161001 | 0.77 | FDPS (0.37) | OPRM1FDPSLMNADNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230159543-A1 | ANTHELMINTIC PYRROLOPYRIDAZINE COMPOUNDS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159543-A1 | ANTHELMINTIC PYRROLOPYRIDAZINE COMPOUNDS | IL5, EPX, MPO | OPRM1 4579/4885FDPS 67/4885SPHK1 1396/4885 |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | OPRM1 2907/4885FDPS 3457/4885SPHK1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.